BACK TO ALL REFERENCES
AllergyVAX: Patient-friendly and cost-efficient allergy vaccination
AllergyVax project includes first-in-human clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine for birch pollen allergy.
€1.9 m
in funding
2.5
years
Key numbers
About the project
The main objective of the AllergyVAX project is to gain first-in-human clinical data of the birch pollen allergy vaccine. It is an important step towards the clinical Proof-of Concept of Desentum’s platform technology. Desentum’s approach is based on using targeted DNA techniques to modify known allergens into so-called hypoallergens. The hypoallergens are expected to improve the safety of desensitization, which usually takes several years but Desentum aims to reduce the time to 3–6 months without compromising safety and efficacy.
Impact of the project:
The benefit of Desentum’s solution is that desensitization process is significantly quicker and more efficient compared to the traditional desensitization practices, which can take up to five years, requiring high commitment which oftentimes are not carried through.
Funding instrument Horizon 2020 SME instrument phase 2
Spinverse’s role
Spinverse helped Desentum to secure €1.9 m in the exceptionally tough Horizon 2020 funding application process: Out of 1,650 proposals only 4 % (66) received the funding. Spinverse supported Desentum in project preparation, including help in defining the scope, business and commercialisation potential as well as assisting in writing the proposal. After a positive decision from EU commission, Spinverse guided Desentum through the complex phase of signing the grant agreement. From Dec 2018, Spinverse supported Desentum with project management for 3 years.
Supporting the UN Sustainable Development Goals
We share what we learn
Read our latest news on our references
